advertisement
The Pfizer coronavirus vaccine is in its “final stages” of getting approval for use in India, informed the company on Tuesday, 22 June.
Addressing a virtual event, Pfizer Chief Executive Officer Albert Bourla said, as per ANI:
The Pfizer vaccine, developed by the company in partnership with the German firm BioNtech, is reported to have a very high efficacy, of over 90 percent.
The Centre had, on 13 May, said that India will produce 216 crore doses of COVID-19 vaccines between August-December.
NITI Aayog member VK Paul had, on his part, said:
These announcements came around the time India was battling a horrific second wave of COVID-19, that resulted in an acute paucity of life-saving resources, as well as space on cremation grounds.
Presently, India is grappling with concerns over a possible third wave, as well as concerns of vaccine shortage, with a small percentage of eligible adults having actually received both jabs so far.
(With inputs from ANI.)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)